Cobimetinib
Cotellic · MEK inhibitor
Real-world AKI signal with BRAF partners.
Zelboraf · Tafinlar · Mekinist · BRAF/MEK
BRAF/MEK inhibitor · approved 2011 · 8 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
Mild but real — vemurafenib carries the strongest tubular signal of the class.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Pharmacovigilance shows vemurafenib > dabrafenib. Mild creatinine elevation common, serious AKI uncommon. Reported rate: acute kidney injury in 21% — 199 patients who received dabrafenib/trametinib in a single large US healthcare system between 2010 and 2019… (Seethapathy 2022, PMID 33355659).Source: Seethapathy et al., Nephrol Dial Transplant 2022
Acute-to-subacute creatinine rise during therapy.
Distilled from: “Acute–subacute during therapy.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Tubular/tubulointerstitial injury is the documented mode of BRAF-inhibitor AKI; FAERS captured 132 vemurafenib and 13 dabrafenib acute kidney injury reports (2011-2014), with vemurafenib apparently more nephrotoxic and injury more common in men. PMID 26182194 (opens PubMed in a new tab)
Hyponatremia (8 vemurafenib, 6 dabrafenib) and hypokalemia (6 and 2) accompanied the AKI reports in the FAERS analysis; electrolyte monitoring is advised with these agents. PMID 26182194 (opens PubMed in a new tab)
Immune-mediated inflammation of the renal interstitium — the signature kidney injury of checkpoint inhibitors.
The great mimic — a rise in creatinine from blocked tubular secretion (OCT2/MATE), NOT true injury. The GFR is intact; confirm with cystatin C before stopping effective therapy.
Global failure of proximal tubule reabsorption — glucosuria, phosphaturia and acidosis, classically from ifosfamide.
Tap a signature to trace where it strikes the nephron.
Representative incidence
Acute Tubular Necrosis strikes: Proximal Tubule, Distal Tubule / Collecting Duct.
Acute Tubular Necrosis
Direct death of tubular epithelial cells — the dose-limiting lesion of the platinums and zoledronate.
Vemurafenib and dabrafenib inhibit mutant BRAF (V600E); trametinib inhibits downstream MEK — shutting down MAPK signaling. BRAF-mutant melanoma and others.
Class-level context for the major non-renal toxicities of the BRAF/MEK inhibitor class.
Dermatologic
Rash, HFS, SJS/TEN, vitiligo
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
Ophthalmic
Keratopathy, uveitis, retinopathy
Vascular
Hypertension, VTE/ATE, bleeding, aneurysm
4 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where BRAF / MEK Inhibitors sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Cotellic · MEK inhibitor
Real-world AKI signal with BRAF partners.
Braftovi · BRAF inhibitor
Class tubular signal; usually mild.
Zelboraf · BRAF inhibitor
Strongest renal offender of the BRAF/MEK class: proximal tubular injury/Fanconi and early AKI.
Tafinlar · BRAF inhibitor
Milder than vemurafenib; pyrexia-driven AKI, rare granulomatous AIN, hyponatremia.
Vidaza · Hypomethylating agent
Proximal (type 2) RTA / Fanconi-like tubulopathy; overt AKI uncommon.
Gleevec · BCR-ABL TKI
Fluid retention; rare Fanconi and AKI.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.
The leading contributors to BRAF / MEK Inhibitors’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on BRAF / MEK Inhibitors; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.
Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 75 clinical records among all 100 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.